Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Diacerein
Therapeutic Area : Dermatology
Study Phase : IND Enabling
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : AC-201 is a novel small molecule inhibitor of TYK2/JAK1 with high activity, selectivity, and safety window. The preclinical studies have shown that AC-201 effectively binds to the pseudo kinase domain (JH2) of TYK2/JAK1.
Product Name : AC-201
Product Type : Microorganism
Upfront Cash : Inapplicable
May 24, 2023
Lead Product(s) : Diacerein
Therapeutic Area : Dermatology
Highest Development Status : IND Enabling
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Diacerein
Therapeutic Area : Rare Diseases and Disorders
Study Phase : Phase II
Sponsor : Hong Kong Winhealth Pharma Group
Deal Size : Undisclosed
Deal Type : Partnership
Winhealth Pharma and TWiB Enter into Strategic Licensing Partnership on AC-203
Details : Strategic partnership grants Winhealth Pharma exclusive right to develop and commercialize rare disease asset AC-203 in mainland China, Hong Kong and Macao for indications including hereditary epidermolysis bullosa (EB), bullous pemphigoid and other skin...
Product Name : AC-203
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
June 01, 2021
Lead Product(s) : Diacerein
Therapeutic Area : Rare Diseases and Disorders
Highest Development Status : Phase II
Sponsor : Hong Kong Winhealth Pharma Group
Deal Size : Undisclosed
Deal Type : Partnership